0000882095
false
0000882095
2020-06-13
2020-06-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): June 14, 2020
Gilead
Sciences, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other jurisdiction
of incorporation)
|
0-19731
(Commission File No.)
|
94-3047598
(IRS Employer
Identification No.)
|
333 Lakeside Drive, Foster City, California
(Address of principal executive offices)
94404
(Zip
Code)
(650) 574-3000
(Registrant’s
telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
Common
Stock, par value, $0.001 per share
|
GILD
|
The Nasdaq
Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
(d) Appointment of
a Director.
On June 14, 2020, the Board of Directors (the Board) of Gilead
Sciences, Inc. (the Company) elected Javier J. Rodriguez to serve on the Board, effective June 15, 2020. There is no arrangement
or understanding between Mr. Rodriguez and any other persons pursuant to which Mr. Rodriguez was selected as a director, and there
are no related party transactions involving Mr. Rodriguez that are reportable under Item 404(a) of Regulation S-K.
Mr. Rodriguez will participate in the Company’s standard
non-employee director compensation programs. Pursuant to these arrangements, as compensation for his service on the Board, Mr.
Rodriguez will receive:
(1) A pro-rated equity grant, consisting of options to
purchase 8,667 shares of the Company’s common stock and restricted stock units covering an additional 1,838 shares of
the Company’s common stock. These grants will be made under the Company’s 2004 Equity Incentive Plan (as amended
and restated, the Plan) and represent his equity compensation for the 2020-2021 service period.
(2) A pro-rated cash retainer in the amount of $3,287.67
for service through June 30, 2020.
A description of the Plan and compensation practices for non-employee
directors can be found in our Definitive Proxy Statement filed with the Securities and Exchange Commission (SEC) on March 24, 2020
in connection with the Company’s 2020 Annual Meeting of Stockholders. The Plan is attached as an exhibit to the Company’s
Current Report on Form 8-K filed with the SEC on May 12, 2017.
A copy of the Company’s press release announcing Mr. Rodriguez’s
election to the Board is attached as Exhibit 99.1 to this report.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
The following exhibit 99.1 is furnished pursuant to this Item
9.01.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
GILEAD SCIENCES, INC.
|
|
|
(Registrant)
|
|
|
|
|
|
/s/ Brett A. Pletcher
|
|
|
Brett A. Pletcher
|
|
|
EVP, Corporate Affairs, General Counsel
and Corporate Secretary
|
Date: June 16, 2020
|
Exhibit 99.1
|
CONTACTS: Douglas Maffei, PhD,
Investors
(650) 522-2739
Marni Kottle,
Media
(650) 522-5388
For Immediate Release
JAVIER RODRIGUEZ JOINS GILEAD SCIENCES’ BOARD OF DIRECTORS
Foster City, Calif., June 16, 2020
– Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Javier Rodriguez has been appointed to the company’s
Board of Directors. Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare
services to kidney disease patients throughout the United States and internationally that strives to improve patients’ quality
of life through clinical innovation and integrated, personalized care. From 2014 to 2019, he was the CEO of DaVita Kidney Care,
the company’s business unit that treats patients with kidney failure and end-stage renal disease. Mr. Rodriguez has spent
more than 20 years in various executive roles at DaVita, driving the company’s transformation for how kidney care is delivered.
In addition, he currently serves as a member of the boards of directors of DaVita and the Denver Metro Chamber of Commerce.
“We are very pleased to welcome Javier
to Gilead's Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “He
brings significant industry expertise and the perspective of a visionary CEO. Javier is a valuable addition to our Board as we
continue to shape Gilead’s next chapter.”
About Gilead Sciences
Gilead Sciences,
Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas
of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the
world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
#
# #
For more information
about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or
call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA
phone 650 574 3000 facsimile 650 578 9264
|
www.gilead.com
|